<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Distributional Treatment Effect Estimation across Heterogeneous Sites via Optimal Transport - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel Optimal Transport-based framework to synthesize counterfactual treatment group data for a target site, overcoming challenges of cr">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Distributional Treatment Effect Estimation across Heterogeneous Sites via Optimal Transport</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.09759v1" target="_blank">2511.09759v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-12
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Borna Bateni, Yubai Yuan, Qi Xu, Annie Qu
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> stat.ME, math.ST, stat.ML
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.90 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.09759v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.09759v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel Optimal Transport-based framework to synthesize counterfactual treatment group data for a target site, overcoming challenges of cross-site heterogeneity in treatment effects. By leveraging full treatment and control data from a source site alongside control data from the target, the method learns a push-forward transformation to generate a synthetic target treatment distribution. This approach robustly recovers the full distributional properties of treatment effects, departing from conventional average treatment effect estimation.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This framework is crucial for enhancing the generalizability of clinical research findings across diverse patient populations and settings, a significant hurdle in evidence-based medicine. It allows for more precise predictions of treatment responses in new cohorts without requiring full trials, thereby accelerating drug development and guiding personalized therapeutic strategies.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This research develops an advanced statistical machine learning framework (using Optimal Transport for distributional causal inference) that can be applied to healthcare data. Specifically, it can be used to: 1) generalize findings from clinical trials conducted in one population to predict treatment outcomes in a different, heterogeneous patient population; 2) accelerate drug discovery and development by enabling more robust predictions of drug efficacy in preclinical models (like patient-derived xenografts) or new patient cohorts; 3) inform personalized medicine by modeling the full distribution of treatment effects, helping identify patient subgroups that may respond differently; and 4) assist in evidence synthesis for healthcare decision-making by intelligently integrating data from various sources.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the challenge of cross-site heterogeneity (effect modification) in estimating treatment effects, which limits the generalizability of findings.</li>
                    
                    <li>Proposes to synthesize counterfactual treatment group data in a target site using full treatment and control data from a source site, combined with control data exclusively from the target site.</li>
                    
                    <li>Adopts a distributional causal inference perspective, modeling treatment and control outcomes as distinct probability measures rather than just focusing on average effects.</li>
                    
                    <li>Utilizes an Optimal Transport (OT) procedure to learn a 'push-forward transformation' that maps the joint feature-outcome distribution from the source to the target site.</li>
                    
                    <li>The transformation is specifically learned by aligning the control group distributions between the source and target sites, and then applied to the source treatment group to generate the synthetic target treatment distribution.</li>
                    
                    <li>Provides theoretical guarantees for the consistency and asymptotic convergence of the synthesized treatment group data to the true target distribution under general regularity conditions.</li>
                    
                    <li>Validated through extensive simulation studies across diverse data-generating scenarios and a real-world application using patient-derived xenograft (PDX) data, demonstrating robust recovery of full distributional treatment properties.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The methodology centers on distributional causal inference, treating treatment and control as distinct probability measures. It employs Optimal Transport (OT) to learn a push-forward transformation. This transformation is derived by aligning the control group distributions between a source and target site. Subsequently, the learned transformation is applied to the source site's treatment group distribution to synthetically generate the counterfactual treatment distribution for the target site.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary finding is the successful development and validation of a framework that consistently and asymptotically synthesizes target site treatment group data, which converges to the true target distribution. This method robustly recovers the full distributional properties of treatment effects, as demonstrated across various simulations and in a real-world application involving patient-derived xenograft data, indicating its practical efficacy in handling complex biological data.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research has significant potential to improve the transferability and applicability of clinical trial results to different patient populations or healthcare settings. It could enable more precise patient stratification and treatment selection in precision medicine by accurately predicting heterogeneous treatment responses. This may reduce the need for extensive, costly, and time-consuming trials in every new population, ultimately accelerating the adoption of effective therapies and facilitating better-informed clinical decisions.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state specific limitations. However, it mentions establishing theoretical guarantees "Under general regularity conditions," implying that the applicability and performance of the method are contingent on these underlying assumptions being met in real-world data.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state future research directions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                    <span class="tag">Clinical Trials</span>
                    
                    <span class="tag">Drug Discovery and Development</span>
                    
                    <span class="tag">Epidemiology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Optimal Transport</span>
                    
                    <span class="tag tag-keyword">Distributional Treatment Effect</span>
                    
                    <span class="tag tag-keyword">Cross-site Heterogeneity</span>
                    
                    <span class="tag tag-keyword">Causal Inference</span>
                    
                    <span class="tag tag-keyword">Effect Modification</span>
                    
                    <span class="tag tag-keyword">Counterfactual Synthesis</span>
                    
                    <span class="tag tag-keyword">Patient-Derived Xenograft</span>
                    
                    <span class="tag tag-keyword">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">We propose a novel framework for synthesizing counterfactual treatment group data in a target site by integrating full treatment and control group data from a source site with control group data from the target. Departing from conventional average treatment effect estimation, our approach adopts a distributional causal inference perspective by modeling treatment and control as distinct probability measures on the source and target sites. We formalize the cross-site heterogeneity (effect modification) as a push-forward transformation that maps the joint feature-outcome distribution from the source to the target site. This transformation is learned by aligning the control group distributions between sites using an Optimal Transport-based procedure, and subsequently applied to the source treatment group to generate the synthetic target treatment distribution. Under general regularity conditions, we establish theoretical guarantees for the consistency and asymptotic convergence of the synthetic treatment group data to the true target distribution. Simulation studies across multiple data-generating scenarios and a real-world application to patient-derived xenograft data demonstrate that our framework robustly recovers the full distributional properties of treatment effects.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>